Product Development
Novavax’s COVID-19 vaccine headed into the clinic; data due in July

Novavax could have preliminary data as soon as July from a planned first-in-human trial of its COVID-19 vaccine, the company said Wednesday.

Next month, ...

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no ...

RNA-targeting small molecule play Arrakis taps Roche as first pharma partner

For its first partnership, RNA-targeting therapeutics developer Arrakis has chosen Roche for a multitarget deal that lands the biotech a $190 million upfront payment, while ...

Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that ...

Keros rises 26% in trading debut during week of market gains

Keros priced an upsized IPO Wednesday and gained $4.08 (26%) to $20.08 despite continued pandemic-driven volatility in the markets.

While the Arca NYSE ...

Wuhan gene therapy play Neurophth raises $18M series A

Neurophth has raised RMB130 million ($18.4 million) in a series A round with plans to bring an ophthalmology gene therapy to market in three to five years.

April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

Scottish protein degradation company raises series A

Amphista Therapeutics Ltd. raised $7.5 million in a series A round led

BioCentury ISSN 1097-7201